Shanghai Fosun Pharmaceutical Group takes significant stake in Simcere; Nephron to build plant in SC;

 @FiercePharma: Shire chairman took home £8.5m. Article via @Guardian | Follow @FiercePharma

> Shanghai Fosun Pharmaceutical Group, which is controlled by Chinese billionaire Guo Guangchang, has taken a 7.5% stake in Simcere Pharmaceutical Group. The news pushed Simcere shares up 3.2% Wednesday to $8.48 on the New York Stock Exchange. Story

> Nephron Pharmaceutical has started a 1.2 million sq. ft., $313 million plant in Lexington County, S.C., which it expects to complete by the end of 2013. It expects to move beyond the generic respiratory drugs it now makes, perhaps into cancer drugs. Story

The API plant of Nobilus in Kutno, Poland, flunked inspection in September, resulting in all drugs produced there being banned from the U.S. with the continuation of an import alert. Story

Biotech News

 @FierceBiotech: Researchers at the University of Bonn coaxed immature brain stem cells from mouse connective tissue. Story | Follow @FierceBiotech

 @JohnCFierce: Interesting piece from @reutersBenHir assessing all the problems with depression drugs. More | Follow @JohnCFierce

 @RyanMFierce: Who likes Durata Therapeutics' chances of pulling off an IPO? Release | Follow @RyanMFierce

@MarkHFierce: So there might be a genetic reason for chronic diarrhea, via MedPageTodayStory | Follow @MarkHFierce

> GSK, Theravance share mixed bag of lung drug data ahead of FDA filing. Article

> $110M therapeutics center on tap for UC San Diego campus. Story

> UPDATED: Addex surges on upbeat data from Parkinson's drug trial. News

> Durata, with license to Pfizer drug, lays plans for $86M IPO. Item

> Depression drug research goes off the rails (again). More

And Finally... The University of California San Diego will build a $110 million, 110,000 sq. ft. Center for Innovative Therapeutics for collaboration amoung academic researchers and biotech and pharma startups. Story